Title: Survival Analysis: Overview of Nonparametric, Parametric, and Semiparametric Approaches
Presenter: Joseph Gardinar (Michigan State University)
Date and Time: Wednesday, June 25, 2014, 12:00 p.m. - 2:00 p.m. Eastern time
Sponsor: Biopharmaceutical Section
Registration Deadline: Monday, June 23, at 12:00 p.m. Eastern time
Description:
Time to event and duration outcomes arise in several fields including biostatistics, demography, economics, engineering and sociology. The terms duration analysis, event-history analysis, failure-time analysis, reliability analysis, and transition analysis refer essentially to the same group of techniques although the emphases in certain modeling aspects could differ across disciplines. In insurance and finance a similar group of techniques apply to the severity of a random event. Simply stated, the outcome of interest is a positive random variable, whose distribution is skewed and the observed outcome might be left or right or interval censored, and or left or right truncated. SASÒ Software offers a suite of procedures for analyses of time to event and severity data. They include LIFETEST, LIFEREG, PHREG, RELIABILITY, SEVERITY, QUANTLIFE and QLIM which have different capabilities and address different needs.
In this webinar we focus on techniques widely used in biostatistics. Methods include Kaplan-Meier estimation, accelerated life-testing models, and the ubiquitous Cox model. Recent developments in SAS extend their reach to include analyses of multiple failure times, recurrent events, frailty models, Markov models and use of Bayesian methods. We present an overview of some of these methods with examples illustrating their application in the appropriate context.
Registration Fees:
Biopharmaceutical Section Members: $44
ASA Members: $59
Nonmembers: $74
Each registration is allowed one web connection and one audio connection. Multiple persons are encouraged to view each registered connection (for example, by projecting the webinar in a conference room).
Access Information
Registered persons will be sent an email the afternoon of Monday, June 23, with the access information to join the webinar and the link to download and print a copy of the presentation slides.
Title: DSMBs/DMCs
Presenter: Scott Evans, Harvard University
Date and Time: Thursday, September 12, 2013, 12:00 p.m. - 2:00 p.m. Eastern time
Sponsor: Biopharmaceutical Section
Registration Deadline: Tuesday, September 10, at 12:00 p.m. Eastern time
Description:
Review of interim clinical trial data has many potential advantages: an ethical attractiveness with potentially fewer patients exposed to possibly harmful or ineffective therapies; economic savings with smaller expected sample sizes and shorter trial durations saving money, time, and other resources; and public health advantages as answers are available more quickly to the medical community. For many years Data Safety Monitoring Boards (DSMBs) or Data Monitoring Committees (DMCs) have played a critical role in the data monitoring process in clinical trials, helping to protect trial participants and providing recommendations to improve the scientific value of trials while preserving scientific integrity. However poor DSMB/DMC practices are common, threatening trial integrity, and leading to sub-optimal recommendations, decision-making, and patient care. In addition, many modern challenges associated with DSMB/DMC processes have emerged (e.g., the role of DSMBs in adaptive designs, the need for DSMB/DMC member indemnification, and appropriate training/experience for DSMB/DMC members). In this webinar I will: define a DSMB/DMC; discuss membership, roles, when SDMBs/DMCs are needed, charters and organization, the importance of an informed and diligent independent statistician, communications and the flow of information, meetings, recommendations, and statistical and operational issues. I will also provide suggestions for planning for meetings and preparing quality reports that will facilitate efficient and effective DMC's evaluation of interim data. In addition, although clear solutions to modern and future challenges are still evolving, I will offer thoughts as to whether changes to DSMB/DMC processes are needed to address these challenges.
Registration Fees:
Biopharmaceutical Section Members: $44
ASA Members: $59
Nonmembers: $74
Each registration is allowed one web connection and one audio connection. Multiple persons are encouraged to view each registered connection (for example, by projecting the webinar in a conference room).
Access Information
Registered persons will be sent an email the afternoon of Tuesday, September 10, with the access information to join the webinar and the link to download and print a copy of the presentation slides.
Title: DSMBs/DMCs
Presenter: Scott Evans, Harvard University
Date and Time: Thursday, September 12, 2013, 12:00 p.m. - 2:00 p.m. Eastern time
Sponsor: Biopharmaceutical Section
Registration Deadline: Tuesday, September 10, at 12:00 p.m. Eastern time
Description:
Review of interim clinical trial data has many potential advantages: an ethical attractiveness with potentially fewer patients exposed to possibly harmful or ineffective therapies; economic savings with smaller expected sample sizes and shorter trial durations saving money, time, and other resources; and public health advantages as answers are available more quickly to the medical community. For many years Data Safety Monitoring Boards (DSMBs) or Data Monitoring Committees (DMCs) have played a critical role in the data monitoring process in clinical trials, helping to protect trial participants and providing recommendations to improve the scientific value of trials while preserving scientific integrity. However poor DSMB/DMC practices are common, threatening trial integrity, and leading to sub-optimal recommendations, decision-making, and patient care. In addition, many modern challenges associated with DSMB/DMC processes have emerged (e.g., the role of DSMBs in adaptive designs, the need for DSMB/DMC member indemnification, and appropriate training/experience for DSMB/DMC members). In this webinar I will: define a DSMB/DMC; discuss membership, roles, when SDMBs/DMCs are needed, charters and organization, the importance of an informed and diligent independent statistician, communications and the flow of information, meetings, recommendations, and statistical and operational issues. I will also provide suggestions for planning for meetings and preparing quality reports that will facilitate efficient and effective DMC's evaluation of interim data. In addition, although clear solutions to modern and future challenges are still evolving, I will offer thoughts as to whether changes to DSMB/DMC processes are needed to address these challenges.
Registration Fees:
Biopharmaceutical Section Members: $44
ASA Members: $59
Nonmembers: $74
Each registration is allowed one web connection and one audio connection. Multiple persons are encouraged to view each registered connection (for example, by projecting the webinar in a conference room).
Access Information
Registered persons will be sent an email the afternoon of Tuesday, September 10, with the access information to join the webinar and the link to download and print a copy of the presentation slides.
Title: DSMBs/DMCs
Presenter: Scott Evans, Harvard University
Date and Time: Thursday, September 12, 2013, 12:00 p.m. - 2:00 p.m. Eastern time
Sponsor: Biopharmaceutical Section
Registration Deadline: Tuesday, September 10, at 12:00 p.m. Eastern time
Description:
Review of interim clinical trial data has many potential advantages: an ethical attractiveness with potentially fewer patients exposed to possibly harmful or ineffective therapies; economic savings with smaller expected sample sizes and shorter trial durations saving money, time, and other resources; and public health advantages as answers are available more quickly to the medical community. For many years Data Safety Monitoring Boards (DSMBs) or Data Monitoring Committees (DMCs) have played a critical role in the data monitoring process in clinical trials, helping to protect trial participants and providing recommendations to improve the scientific value of trials while preserving scientific integrity. However poor DSMB/DMC practices are common, threatening trial integrity, and leading to sub-optimal recommendations, decision-making, and patient care. In addition, many modern challenges associated with DSMB/DMC processes have emerged (e.g., the role of DSMBs in adaptive designs, the need for DSMB/DMC member indemnification, and appropriate training/experience for DSMB/DMC members). In this webinar I will: define a DSMB/DMC; discuss membership, roles, when SDMBs/DMCs are needed, charters and organization, the importance of an informed and diligent independent statistician, communications and the flow of information, meetings, recommendations, and statistical and operational issues. I will also provide suggestions for planning for meetings and preparing quality reports that will facilitate efficient and effective DMC's evaluation of interim data. In addition, although clear solutions to modern and future challenges are still evolving, I will offer thoughts as to whether changes to DSMB/DMC processes are needed to address these challenges.
Registration Fees:
Biopharmaceutical Section Members: $44
ASA Members: $59
Nonmembers: $74
Each registration is allowed one web connection and one audio connection. Multiple persons are encouraged to view each registered connection (for example, by projecting the webinar in a conference room).
Access Information
Registered persons will be sent an email the afternoon of Tuesday, September 10, with the access information to join the webinar and the link to download and print a copy of the presentation slides.